Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LUF6000 is an allosteric modulator of the human A3 adenosine receptor (AR).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | 6-8 weeks | $ 327.00 | |
25 mg | 6-8 weeks | $ 767.00 | |
50 mg | 6-8 weeks | $ 997.00 | |
100 mg | 6-8 weeks | $ 1,750.00 | |
1 mL * 10 mM (in DMSO) | 6-8 weeks | $ 358.00 |
Description | LUF6000 is an allosteric modulator of the human A3 adenosine receptor (AR). |
In vitro | LUF6000 converted a nucleoside A3 AR antagonist MRS542, but not a non-nucleoside antagonist MRS1220, into an agonist. LUF6000 exerted an Emax-enhancing effect at a concentration of 0.1 microM or higher and was shown to increase the Emax of Cl-IB-MECA and other low-efficacy agonists to a larger extent than that of the high-efficacy agonist NECA. A3 adenosine receptor LUF6000 was found to be an allosteric enhancer of Emax of structurally diverse agonists at the A3 AR, being more effective for low-Emax agonists than for high-Emax agonists. |
Molecular Weight | 411.33 |
Formula | C22H20Cl2N4 |
CAS No. | 890087-21-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 14.29 mg/mL (34.74 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
LUF6000 890087-21-5 Others LUF-6000 LUF 6000 inhibitor inhibit